Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

PARP1 inhibitor

DRUG CLASS:

PARP1 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA1 mutation	Peritoneal Cancer	BRCA1 mutation	Peritoneal Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA2 mutation	Peritoneal Cancer	BRCA2 mutation	Peritoneal Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA2 mutation	Fallopian Tube Cancer	BRCA2 mutation	Fallopian Tube Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA1 mutation	Fallopian Tube Cancer	BRCA1 mutation	Fallopian Tube Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA2 mutation	Pancreatic Cancer	BRCA2 mutation	Pancreatic Cancer	BSI 201 Sensitive: C4 – Case Studies BSI 201 Sensitive : C4	BSI 201 Sensitive: C4 – Case Studies BSI 201 Sensitive : C4
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D